Replies to post #208444 on Biotech Values

[DewDiligence]

ABBV’s 2017 Viekira sales guidance is $1.0B, implying a further slowdown from the 4Q16 run rate. For ENTA investors, G/P can’t come soon enough.

[DewDiligence]

Viekira* Sales by Calendar Quarter ($ M)

 
          ---TOTAL--  ----US----  ---Ex-US--  
 Quarter  Sales QoQ%  Sales QoQ%  Sales QoQ% 
   1Q17     263 -15%     38 -30%    225 -12%

4Q16 311 -18% 54 -29% 257 -15%
3Q16 378 -10% 76 -13% 302 -9%
2Q16 419 +1% 87 -30% 332 +15%
1Q16 414 -26% 125 -37% 289 -19%
4Q15 554 +18% 197 -19% 357 +57%
3Q15 469 +21% 242 +7% 227 +44%
2Q15 385 +67% 227 +64% 158 +70%
1Q15 231 -- 138 -- 93 --*Includes Viekira Pak, Technivie and Viekirax.

Source: http://finance.yahoo.com/m/3a691b3d-e2e6-3147-9326-c0d47e838a6d/ss_market-recon%3A-the-tax-reform.html